Zydus Cadila has received a green signal from United States Federal Drug Administration (USFDA) to market its Bromocriptine Mesylate Capsules 5 mg in the United States. The drug falls in women healthcare segment and is also used in adjunct therapy in CNS segment. The market for Bromocriptine Mesylate is around $11.7 million in the United States.
The company has so far received 40 approvals from USFDA and total number of filings for approval with USFDA is 79, since 2003-04.
